Compare Teucrium Soybean Fund (SOYB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs Travere Therapeutics Inc. Common Stock — how do they compare? Teucrium Soybean Fund trades at $27.15 (market cap $43.12M), while Travere Therapeutics Inc. Common Stock trades at $54.69 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 116.4× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Soybean Fund for 25 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SOYB | TVTX | |
|---|---|---|
Market Cap | $43.12M | $5.02B |
Volume | 52,920 | 2,060,842 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $28.14 | $67.52 |
52-Week Low | $21.59 | $26.79 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
